Candel Therapeutics IncCADL
Price$10.16

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$88.5MTTM through 30 Jun 2026
Free Cash Flow -$57.3MTTM through 30 Jun 2026

Margins

Current

Returns

-73.6%ROE
-30.5%ROA

Balance Sheet Health

Debt / Equity0.91x
Current Ratio13.49x
Net Debt-$72.6Mnet cash position
Cash & Equivalents$201.6M

Quality Metrics

Altman Z-Score4.72
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'20'21'22
FY2022: $125K
Diluted EPS-$1.47TTM
'21'22'23'24'25
FY2025: $-0.72

Dividend

No dividend

Capital Allocation

R&D Spend$49.1M

Segment Performance

SegmentRevenueYoYOutlook
Multimodal Immunotherapies$0
View details

Pre-commercialization and clinical trial activities are expected to accelerate ahead of potential 2027 launch.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.